Prostate cancer is a major public health concern. Prostate cancer is the most commonly diagnosed and second leading cause of cancer deaths in U.S. men.1 Approximately 1 man in 8 will be diagnosed with prostate cancer in his lifetime.2 Approximately 76% of prostate cancer cases are diagnosed in early stage. The 5 year survival rate for all stages is 97.8%.2
We offer a wide menu of immunohistochemistry (IHC) assays. Our portfolio of products delivers the high sensitivity and specificity you need.
Our antibodies are ready to use on the fully automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions. We have a robust assay development program focusing on immunohistochemical staining, clinical reagents, cancer diagnostic assays, and much more.